Halper Sadeh Launches Investigations into Payoneer, Bio-Techne, and CBAN

The firm is examining whether these deals prioritize insider benefits over the interests of ordinary investors. Specific concerns center on whether existing terms unfairly restrict superior competing offers. For Payoneer Global, the investigation focuses on a cash-out sale to Nuvei at $7.40 per share, while the scrutiny of Bio-Techne involves its $73.00 per share acquisition by Merck KGaA. Regarding Colony Bankcorp, the focus remains on the structural implications of its merger with First Reliance Bancshares.

Halper Sadeh attorneys, led by Daniel Sadeh and Zachary Halper, are evaluating whether to seek increased financial consideration or additional disclosures for affected shareholders. The firm operates on a contingent fee basis for these inquiries, signaling a push for potential litigation or corporate reform to address alleged violations of federal securities laws.